Form 8-K - Current report:
SEC Accession No. 0001628280-21-003894
Filing Date
2021-03-04
Accepted
2021-03-04 08:23:05
Documents
16
Period of Report
2021-03-04
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20210304.htm   iXBRL 8-K 38875
2 EX-99.1 a991pressreleasedatedmarch.htm EX-99.1 100482
8 x4logo1a.jpg GRAPHIC 9468
  Complete submission text file 0001628280-21-003894.txt   310144

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20210304.xsd EX-101.SCH 2423
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20210304_cal.xml EX-101.CAL 710
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20210304_def.xml EX-101.DEF 1643
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20210304_lab.xml EX-101.LAB 25998
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20210304_pre.xml EX-101.PRE 13731
9 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20210304_htm.xml XML 12137
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 21712649
SIC: 2836 Biological Products, (No Diagnostic Substances)